
The U.S. Food and Drug Administration (FDA) today approved the CAR T-cell treatment axicabtagene ciloleucel (Yescarta®) for patients with follicular lymphoma (FL) that has returned or worsened despite earlier treatment. FL is the most common slow-growing non-Hodgkin’s lymphoma and while the disease can generally be managed, reoccurrence is common. LLS was among the first to invest in CAR T in the 1990’s. Today, the therapy has rapidly become a mainstay of cancer care. LLS supported cl...